Dihexa is a modified fragment of angiotensin IV, made by researchers at Washington State University to be taken by mouth and to cross into the brain. It has been studied only in cells and animals and is not approved for human use.
Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide.
For dihexa, there is no approved product and no published human study, so there are no label strengths or studied human amounts.
Dihexa is not FDA approved, and we could not find any published study that gave it to people.
The two papers that introduced it reported reversal of memory deficits in rat models (McCoy 2013) and proposed that it works through hepatocyte growth factor (HGF) and its receptor, c-Met (Benoist 2014). In 2021 the journal published an expression of concern about both papers, and in 2025 it retracted the 2014 paper. A separate 2021 study (Sun) reported better spatial learning in a mouse model of Alzheimer's disease. Mouse and rat results often do not carry over to people.
We could not find a published human half-life for this compound. Figures quoted online usually come from animal or cell studies, so we do not list one here.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator